JWJonas Wilkening

Jonas Wilkening

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonas Wilkening has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Roberto Goya-Maldonado

    Laboratory of Systems Neuroscience and Imaging in Psychiatry (SNIP-Lab), Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany

    6 shared publications
  • Alexander Sartorius

    Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

    2 shared publications
  • Bruno Pedraz-Petrozzi

    Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

    2 shared publications
  • Martijn Arns

    Heart & Brain Group, Brainclinics Foundation, Nijmegen, The Netherlands

    2 shared publications
  • Anja Lok

    Amsterdam UMC, University of Amsterdam, Adult Psychiatry, Meibergdreef 9, Amsterdam 1105AZ, the Netherlands; Amsterdam Neuroscience, Mood, Anxiety, Psychosis, Stress and Sleep, Amsterdam, the Netherlands; Center for Urban Mental Health, University of Amsterdam, the Netherlands

    1 shared publication
  • Anna Wunderlich

    Laboratory of Systems Neuroscience and Imaging in Psychiatry (SNIP-Lab), Department of Psychiatry and Psychotherapy, University Medical Center Göttingen (UMG), Von-Siebold-Straße 5, 37075 Göttingen, Germany

    1 shared publication

Latest Publications

  • Open Access

    White matter tracts associated with iTBS-induced heart rate deceleration and treatment response in major depressive disorder

    by Jonas Wilkening, Roberto Goya-Maldonado

    Intermittent theta burst stimulation (iTBS) is a well-established treatment for major depressive disorder (MDD), but predicting clinical outcomes remains challenging. Heart rate deceleration induced by iTBS has emerged as a potential biomarker for treatment response, yet the role of white matter (WM) properties in mediating these effects is largely unexplored. In this quadruple-blind, crossover study, we investigated the relationship between WM microstructure, iTBS-driven heart rate modulation, and antidepressant effects. Using correlational tractography, we focused on four major WM tracts—the cingulum, fornix, superior longitudinal fasciculus, and uncinate fasciculus—to examine short-term microstructural changes in relation to therapeutic outcomes. At baseline, findings revealed that fractional anisotropy (FA) in the fornix and right dorsal cingulum was negatively correlated with heart rate deceleration, while radial and mean diffusivity (MD, RD) in the fornix were positively correlated. In the right ventral cingulum, FA showed a positively correlation, while MD and RD were negatively correlated with symptom improvement. Longitudinally, FA increases in the left cingulum were significantly associated with greater symptom alleviation post-treatment. Notably, the correlation between iTBS-induced heart rate modulations and clinical improvement after six weeks, previously demonstrated in this cohort, was identified, while WM microstructural properties in the fornix and cingulum demonstrated predictive value for both heart rate modulation and treatment response. WM changes in the cingulum, evident as early as four weeks, highlight its unique neuroplasticity potential along iTBS intervention. Together, these findings provide novel insights into the structural connectivity patterns influencing iTBS outcomes, offering a novel foundation for more personalized therapeutic strategies in MDD.


  • Open Access

    Heart rate modulation and clinical improvement in major depression: A randomized clinical trial with accelerated intermittent theta burst stimulation

    by Jonas Wilkening, Henrike M. Jungeblut, Ivana Adamovic, Vladimir Belov, Peter Dechent, Lara Eicke, Niels Hansen, Vladislav Kozyrev, Lara E. Marten, Yonca Muschke, et al.

    Intermittent theta burst stimulation (iTBS) is a promising noninvasive treatment for major depressive disorder (MDD), though significant variability exists in patient responses. This quadruple-blind, sham-controlled crossover randomized clinical trial investigated whether clinical improvement was influenced by the spatial selection of stimulation sites or early cardiac rhythm modulations. Seventy-five patients with MDD (33 women) were randomized to either personalized stimulation sites—identified via the strongest negative functional connectivity between the left dorsolateral prefrontal cortex and the default mode network—or fixed stimulation at the F3 position of the 10–20 EEG system. Electrocardiograms throughout stimulation monitored heart rate and its variability, focusing on heartbeat deceleration heart rate (RR) slope and changes in the root mean square of successive differences between heartbeats (RMSSD). Findings demonstrated that a higher RR slope within the first 45 s of stimulation predicted greater clinical improvement at 6 weeks, while a lower RMSSD change during the first 270 s correlated with improvement at 1 week. However, no significant differences in outcomes were observed between personalized and fixed stimulation sites. This study identified a significant relationship between early heart rhythm modulations and the antidepressant effects of accelerated iTBS in MDD. Although the spatial determination of stimulation sites did not enhance clinical improvement, iTBS-induced changes in cardiac rhythm during early sessions may develop into valuable biomarkers for stratifying patients, enabling more personalized and effective treatment strategies in the future.


  • Open Access

    Baseline White Blood Cell as a Moderator of Heart-Brain Coupling-Related Response in Depression

    by Bruno Pedraz-Petrozzi, Jonas Wilkening, Alexander Sartorius, Martijn Arns, Roberto Goya-Maldonado

    Background: Low-grade inflammation occurs in ∼30% of individuals with major depressive disorder (MDD) and is linked to poorer treatment outcomes, autonomic dysregulation, and elevated cardiometabolic risk. Such inflammation may contribute to variability in response to intermittent theta burst stimulation (iTBS) of the left dorsolateral prefrontal cortex. We tested whether baseline inflammation moderates the association between heart–brain coupling (HBC) during iTBS and clinical improvement, and examined neuroimaging correlates of inflammatory status. Methods: Inflammation was indexed using routine clinical markers: white blood cell count (WBC) and C-reactive protein (CRP). HBC, a physiological marker of frontal-vagal engagement, was derived from electrocardiographic recordings obtained during the first iTBS sessions. Diffusion MRI free-water metrics were used to assess white-matter microstructural alterations associated with inflammation. Results: Higher HBC was associated with symptom improvement only among individuals with lower WBC. Patients with higher WBC counts showed elevated free-water diffusion MRI signal in the fornix and corpus callosum, suggesting possible inflammation-related white matter differences warranting replication. Conclusions: Baseline WBC moderated the association between HBC and clinical response and may contribute to inter-individual variability in iTBS outcomes. Routine inflammatory markers could support stratification approaches for biomarker-guided neuromodulation in MDD. HIGHLIGHTS: Baseline WBC moderates HBC–iTBS response in major depression High HBC was associated with improvement primarily at lower WBC levels (≈<6.44×10□/L) CRP does not significantly moderate HBC–response associations Exploratory DTI analyses linked higher WBC to increased free-water in the fornix & corpus callosum WBC may be a candidate low-cost stratification marker for future biomarker-guided neuromodulation studies.

  • Open Access

    Baseline Inflammatory Profiles in Moderate-to-Severe Depression and Differential Response to Intermittent Theta-Burst Stimulation

    by Bruno Pedraz-Petrozzi, Jonas Wilkening, Nicole Ziegler, Martijn Arns, Alexander Sartorius, Roberto Goya-Maldonado

    Background Major depressive disorder (MDD) is a disabling condition characterized by marked heterogeneity in treatment response. Inflammatory signaling pathways—such as cytokine–cytokine receptor interactions, JAK/STAT, and NF-κB activation—have been implicated in treatment resistance, particularly in severe depression. It remains unclear whether baseline inflammatory profiles can distinguish subgroups with variable outcomes following intermittent theta burst stimulation (iTBS), a non-invasive neuromodulatory treatment. Methods In this exploratory study, we applied k-means clustering to baseline inflammatory protein expression data (Olink® Target 96 Inflammation panel) in patients with severe MDD undergoing iTBS. Clinical and general characteristics were compared across clusters. Differentially expressed proteins were identified using volcano plots with false discovery rate (FDR) correction. Kyoto Encyclopedia of Genes and Genomes and Reactome enrichment analyses identified biological pathways associated with each cluster. Results Four inflammatory subgroups were identified. Cluster 1 had the highest proportion of treatment response; Cluster 4, the lowest. Clusters did not differ significantly by age, sex, medication, randomization, or BMI. Volcano plot analysis revealed 28 differentially expressed proteins (FDR < 0.05), with nine showing robust differences (e.g., IL-8, MCP-4, MMP-1, CXCL11, IL-7; |NPX difference| > 1). Enrichment analyses implicated cytokine-cytokine receptor interaction, chemokine signaling, and interleukin signaling pathways in the non-responders group. Limitations Exploratory design, small sample size, and absence of a treatment control group are the main limitations. Lifestyle factors may have influenced immune markers. Conclusions Baseline inflammatory profiles may differentiate iTBS treatment response in severe MDD, supporting immune-based stratification as a step toward personalized psychiatry.

  • Top Cited Papers
    Open Access

    Theta burst stimulation for depression: a systematic review and network and pairwise meta-analysis

    by Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Jonas Wilkening, Roberto Goya-Maldonado, Martin Tik, Nolan R. Williams, Shinsuke Kito, et al.

    In clinical practice, theta burst stimulation (TBS) presents as a more efficient and potentially more effective therapeutic modality than conventional repetitive transcranial magnetic stimulation (rTMS), as it allows for the delivery of more stimuli in less time and at similar intensities. To date, accelerated treatment plans according to various continuous (cTBS) and intermittent TBS (iTBS) protocols for depression have been proposed. To investigate which of the TBS protocols provided a favorable risk-benefit balance for individuals with depression, this systematic review and random-effects model network meta-analysis was conducted. The study outcomes included response rate (primary), depression symptom improvement, remission rate, all-cause discontinuation rate, incidence of switch to mania, and incidence of headache/discomfort at treatment site. In this meta-analysis, a total of 23 randomized controlled trials (n = 960, mean age = 41.88 years, with 60.78% females) were included. Approximately 69.57% of the trials included individuals with an exclusive diagnosis of major depressive disorder. The following six TBS protocols (target) were evaluated: cTBS (right-dorsolateral prefrontal cortex [R-DLPFC]), cTBS (R-DLPFC) + iTBS (left-DLPFC [L-DLPFC]), iTBS (L-DLPFC), iTBS (L-DLPFC) + iTBS (R-DLPFC), iTBS (left-dorsomedial prefrontal cortex) + iTBS (right-dorsomedial prefrontal cortex), and iTBS (occipital lobe). Compared to sham, cTBS (R-DLPFC) + iTBS (L-DLPFC), iTBS (L-DLPFC), and iTBS (occipital lobe) had a higher response rate (k = 23); cTBS (R-DLPFC) + iTBS (L-DLPFC) and iTBS (L-DLPFC) dominated in the depression symptom improvement (k = 23); and iTBS (L-DLPFC) had a higher remission rate (k = 15). No significant differences were found for all-cause discontinuation rate (k = 17), incidence of switch to mania (k = 7), and incidence of headache/discomfort at treatment site (k = 10) between any TBS protocols and sham. Thus, cTBS (R-DLPFC) + iTBS (L-DLPFC) and iTBS (L-DLPFC) demonstrate favorable risk-benefit balance for the treatment of depression.


  • Open Access

    Accelerated intermittent theta burst stimulation in major depressive disorder: A systematic review

    by Daan Neuteboom, Jasper B. Zantvoord, Roberto Goya-Maldonado, Jonas Wilkening, Annemieke Dols, Eric van Exel, Anja Lok, Lieuwe de Haan, Karel W.F. Scheepstra